Torasemide | CAS#56211-40-6

MedKoo Cat#: 318892 | Name: Torasemide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Torasemide is a pyridine-sulfonyl urea type loop diuretic mainly used in the management of edema associated with congestive heart failure. It is also used at low doses for the management of hypertension.

Chemical Structure

Torasemide

CAS#56211-40-6

Theoretical Analysis

MedKoo Cat#: 318892

Name: Torasemide

CAS#: 56211-40-6

Chemical Formula: C16H20N4O3S

Exact Mass: 348.1256

Molecular Weight: 348.42

Elemental Analysis: C, 55.16; H, 5.79; N, 16.08; O, 13.78; S, 9.20

Price and Availability

Size	Price	Availability
1g	USD 250.00	2 Weeks
2g	USD 450.00	2 Weeks
5g	USD 750.00	2 Weeks
10g	USD 1,250.00	2 Weeks
100g	USD 4,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Torasemide, Torsemide, Demadex, Diuver, Examide, Luprac

IUPAC/Chemical Name

1-[4-(3-methylanilino)pyridin-3-yl]sulfonyl-3-propan-2-ylurea

InChi Key

NGBFQHCMQULJNZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)

SMILES Code

O=C(NC(C)C)NS(=O)(C1=C(NC2=CC=CC(C)=C2)C=CN=C1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 348.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Pradhan A, Jaiswal A, Bhandari M. TRANSFORM-HF Trial: Choice of loop diuretic in acute heart failure does not matter! J Family Med Prim Care. 2024 Oct;13(10):4149-4153. doi: 10.4103/jfmpc.jfmpc_211_24. Epub 2024 Oct 18. PMID: 39629454; PMCID: PMC11610876. 2: Schröder L, Seifert R. The 10 top prescribed medicines in Germany from 1985 to 2022: pharmacological analysis. Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov 21. doi: 10.1007/s00210-024-03615-5. Epub ahead of print. PMID: 39570381. 3: Li T, Zhang M, Zhang T, Li S, Kou C, Zhao M, Huang J, Cao W, Jin P. Cyclin- dependent kinase 4/6 inhibitors and cardiotoxic events in breast cancer: A pharmacovigilance study based on the FAERS database. Int J Cancer. 2024 Nov 13. doi: 10.1002/ijc.35255. Epub ahead of print. PMID: 39538367. 4: Tolić Čop K, Pranjić M, Vianello R, Stražić Novaković D, Mutavdžić Pavlović D. Elimination of torasemide from aqueous medium: influence of sorption and photocatalytic processes parameters supported by DFT analysis. Environ Sci Pollut Res Int. 2024 Nov;31(54):63176-63194. doi: 10.1007/s11356-024-35356-6. Epub 2024 Oct 30. PMID: 39476160. 5: Aksenova AV, Oschepkova EV, Chazova IE. [Antihypertensive therapy in patients with arterial hypertension and concomitant diseases in real clinical practice (according to the National Registry of Arterial Hypertension, 2019-2022)]. Ter Arkh. 2024 Oct 10;96(9):860-871. Russian. doi: 10.26442/00403660.2024.09.202848. PMID: 39467240. 6: Gottlieb M, Moyer E, Bernard K. Epidemiology of heart failure presentations to United States emergency departments from 2016 to 2023. Am J Emerg Med. 2024 Dec;86:70-73. doi: 10.1016/j.ajem.2024.09.059. Epub 2024 Sep 30. PMID: 39366035. 7: Nouhravesh N, Greene SJ, Clare R, Wojdyla D, Anstrom KJ, Velazquez E, Pitt B, Mentz RJ, Psotka MA. Diuretic dosing and outcomes with torsemide and furosemide following hospitalization for heart failure: The TRANSFORM-HF trial. Eur J Heart Fail. 2024 Oct 4. doi: 10.1002/ejhf.3458. Epub ahead of print. PMID: 39363809. 8: Banerjee S, Navasundi GB, Vora A, Arneja J, Sharma K, Jaswal A, Kannan K, Kumar P, Bharti BB, Singh UN, Garg R, Aila P, Zalte N, Sugumaran A. Fixed-dose Combination of Torsemide and Mineralocorticoid Receptor Antagonists. J Assoc Physicians India. 2024 Sep;72(9S):40-42. doi: 10.59556/japi.72.0678. PMID: 39291574. 9: Vora A, Sharma A, Sivakadaksham, Sundar RH, Mandal SC, Chatterjee N, Agarwal A, Bhatnagar MK, Gupta A, Thaploo R, Francis F, Mohanasundaram S. Torsemide in the Management of Pulmonary Edema. J Assoc Physicians India. 2024 Sep;72(9S):38-39. doi: 10.59556/japi.72.0677. PMID: 39291573. 10: Bhattacharyya K, Tiwaskar M, Datta A, Chandani AL, Agrawal SK, Abdullakutty J, Badani R, Doshi D, Singh V, Advani P, Varghese K, Pandey AK, Francis F, Sugumaran A. Torsemide in the Management of Essential Hypertension. J Assoc Physicians India. 2024 Sep;72(9S):35-37. doi: 10.59556/japi.72.0676. PMID: 39291572. 11: Upadhyay R, Tiwaskar M, Dargad R, Ghosh U, Jain DK, Galla RK, Haricharan G, Sharma J, Thakker M, Zalte N, Mohanasundaram S. Torsemide in Edema Associated with Hepatic Impairment. J Assoc Physicians India. 2024 Sep;72(9S):32-34. doi: 10.59556/japi.72.0675. PMID: 39291571. 12: Chafekar D, Mukhopadhyay P, Ambekar N, Kumar S, George J, Khullar D, Saxena S, Shah J, Mavani S, Ruhela V, Goyal M, Francis F, Mohanasundaram S. Torsemide in Edema Associated with Chronic Kidney Disease. J Assoc Physicians India. 2024 Sep;72(9S):27-31. doi: 10.59556/japi.72.0674. PMID: 39291570. 13: Agarwal JK, Reddy GM, Kapoor A, Bhattacharya D, Chandorkar AB, Desai B, Sharma S, Marwaha R, Passey R, Vishwakarma P, Guruswami R, Zalte N, Sugumaran A. Emerging Role of Low-dose Loop Diuretics in the Management of Heart Failure Patients to Maintain Euvolemia. J Assoc Physicians India. 2024 Sep;72(9S):24-26. doi: 10.59556/japi.72.0673. PMID: 39291569. 14: Ezhilan J, Dighe S, Shah C, Tiwaskar M, Chopra V, Patil R, Srivastava P, Mahilmaran A, Pradhan A, Rahman S, Malviya A, Gupta A, Teja P, Francis F, Sugumaran A. Torsemide as a Primary Choice in Edema Associated with Heart Failure. J Assoc Physicians India. 2024 Sep;72(9S):19-23. doi: 10.59556/japi.72.0672. PMID: 39291568. 15: Lal M, Sahoo PK, Tiwaskar M, Nisty N, Golwala S, Banerjee S, Krishna R, Mehta A, Kumar A, Garg N, Arumugam G, Khan IA, Zalte N, Mohanasundaram S. Unique Pharmacological Properties and Safety Profiles of Loop Diuretics. J Assoc Physicians India. 2024 Sep;72(9S):16-18. doi: 10.59556/japi.72.0671. PMID: 39291567. 16: Solanki D, Choudhary S, Vora A, Ghose T, Mantri RR, Modi N, Sawhney J, Singhal A, Kumar A, Edakutty R, Pande A, Ahuja R, Francis F, Mohanasundaram S. Loop Diuretics Unique Mechanism of Action. J Assoc Physicians India. 2024 Sep;72(9S):14-15. doi: 10.59556/japi.72.0670. PMID: 39291566. 17: Pal J, Tiwaskar M, Garg S, Khare AN, Patil S, Bhutani J, Gupta A, Srinivas S, Nambirajan G, Reddy R, Singh AP, Kashyap U, Zalte N, Sugumaran A. Loop Diuretics: An Overview of Its History and Evolution. J Assoc Physicians India. 2024 Sep;72(9S):11-13. doi: 10.59556/japi.72.0669. PMID: 39291565. 18: Gogtay J. Preface. J Assoc Physicians India. 2024 Sep;72(9S):7. doi: 10.59556/japi.72.0680. PMID: 39291563. 19: Bansal S. Guest Editorial. J Assoc Physicians India. 2024 Sep;72(9S):6. doi: 10.59556/japi.72.0679. PMID: 39291562. 20: Zakrocka I, Targowska-Duda KM, Kocki T, Turski W, Urbańska EM, Załuska W. Loop diuretics inhibit kynurenic acid production and kynurenine aminotransferases activity in rat kidneys. Pharmacol Rep. 2024 Dec;76(6):1415-1428. doi: 10.1007/s43440-024-00648-8. Epub 2024 Sep 11. PMID: 39261392; PMCID: PMC11582277.